|Bid||3.9900 x 1300|
|Ask||4.1900 x 2900|
|Day's Range||3.8500 - 4.2990|
|52 Week Range||1.5600 - 9.2000|
|Beta (3Y Monthly)||1.54|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
CORAL GABLES, FL / ACCESSWIRE / March 18, 2019 / The tech stock market is truly miraculous, mainly because the tech industry never ceases to amaze consumers as companies consistently demonstrate their ability to innovate towards the future. Over the course of the last few months, we've seen tech companies design and invent in the areas of data analytics, artificial intelligence, augmented reality, and a plethora of others. ParcelPal Technology Inc (PTNYF) (PKG), Conformis Inc (CFMS), Digital Turbine Inc (APPS), and Akari Therapeutics Plc (AKTX) represent 4 tech stocks on the rise on Monday.
Every investor in Akari Therapeutics, Plc (NASDAQ:AKTX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tendRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 13) Abbott Laboratories (NYSE: ABT ) Akari Therapeutics ...
CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The future of the tech stock market directly related to the ability of companies in the tech industry to combat the growing obstacles facing humanity. In ...
Shares of Akari Therapeutics PLC more than doubled--soaring 145%--toward a 15-month high in very active morning trade Wednesday, enough to pace all the gainers on the Nasdaq exchange, after the company said it plans to commence trials in European and U.S. pediatric patients this year for its treatment of pediatric thrombotic microangiopathy. Trading volume rocketed to 22.3 million shares, compared with the full-day average of about 20,000 shares. The company said it had a "successful," pre-investigational new drug (IND) meeting with the Food and Drug Administration regarding its pivotal clinical trial program for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), which is an orphan condition with an estimated fatality rate of 80%. Chief Executive Clive Richardson said trials in HSCT-TMA patients are planned to begin in the fourth quarter. "We see HSCT-TMA as a gateway indication into a range of other poorly treated orphan TMAs, and are enthusiastic about the potential of Coversin to offer an improved standard of care for patients with these rare and usually fatal conditions," Richardson said. The stock has now run up 93% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has slipped 1.1% and the S&P 500 gained 0.9%.
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces that it had a successful Type B, pre-IND meeting with the Food and Drug Administration (FDA) regarding Akari’s proposed pivotal clinical trial program for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).
NEW YORK, Feb. 21, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.
If you own shares in Akari Therapeutics, Plc (NASDAQ:AKTX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and or leukotriene systems are implicated, today announced that PASylated Coversin data will be presented at the 2nd Annual 2018 Complement-Based Drug Development Summit in Boston, Mass. during an oral presentation by Andrew Luster, M.D., Ph.D., Chief, Division of Rheumatology, Allergy and Immunology & Director, Center for Immunology and Inflammatory Diseases Massachusetts General Hospital. Akari currently has two clinical programs open in bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) where both C5 and LTB4 are believed to be implicated.
Akari Therapeutics Plc’s (NASDAQ:AKTX) latest earnings announcement in December 2017 confirmed company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Below, I’veRead More...